glp 1 approved for cardiovascular disease While GLP-1 drugs are known to help manage blood glucose levels and weight, new research shows they also offer heart-protective benefits. The FDA has four GLP-1 drugs to help prevent serious Cardiovascular and mortality outcomes with

Another condition associated with GLP-1 receptor agonists is bowel obstruction

Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms

Cranbury, NJ

[4] showed that MT knockout in mice resulted in higher body weight during the early stages of life, with a greater potential for obesity when consuming a high-fat diet

Storing near heat sources accelerates chemical degradation